Cinacalcet Hydrochloride
FDA Label NDC 70436-007

46 label sections · Submitted to the FDA by Slate Run Pharmaceuticals · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Slate Run Pharmaceuticals for the product Cinacalcet Hydrochloride (NDC 70436-007). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding 1.1 secondary hyperparathyroidism, 1.2 parathyroid carcinoma, 1.3 primary hyperparathyroidism, 2.1 administration, 2.2 secondary hyperparathyroidism in patients with chronic kidney disease on dialysis, 2.3 patients with parathyroid carcinoma and primary hyperparathyroidism, 2.4 switching from parsabiv (etelcalcetide) to cinacalcet tablets, 2.5 monitoring for hypocalcemia, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

Label Section Quick Index

1.3 Primary Hyperparathyroidism

Cinacalcet tablets are indicated for the treatment of hypercalcemia in adult patients with primary HPT for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo parathyroidectomy [see Clinical Studies (14.3)].

2.1 Administration

Cinacalcet tablets should be taken with food or shortly after a meal.

Cinacalcet tablets are administered orally and should always be taken whole and not chewed, crushed, or divided.

2.4 Switching From Parsabiv (Etelcalcetide) To Cinacalcet Tablets

Discontinue etelcalcetide for at least 4 weeks prior to starting cinacalcet tablets. Ensure corrected serum calcium is at or above the lower limit of normal prior to cinacalcet tablets initiation [see Warnings and Precautions (5.1)]. Initiate cinacalcet tablets treatment at a starting dose of 30 mg once daily.

5.2 Upper Gastrointestinal Bleeding

Cases of gastrointestinal bleeding, mostly upper gastrointestinal bleeding, have occurred in patients using calcimimetics, including cinacalcet tablets, from postmarketing and clinical trial sources. The exact cause of GI bleeding in these patients is unknown.

Patients with risk factors for upper GI bleeding (such as known gastritis, esophagitis, ulcers or severe vomiting) may be at increased risk for GI bleeding when receiving cinacalcet tablet treatment. Monitor patients for worsening of common GI adverse reactions of nausea and vomiting associated with cinacalcet tablets [see Adverse Reactions (6.1)] and for signs and symptoms of GI bleeding and ulcerations during cinacalcet tablet therapy. Promptly evaluate and treat any suspected GI bleeding.

5.3 Hypotension, Worsening Heart Failure And/Or Arrhythmias

In postmarketing safety surveillance, isolated, idiosyncratic cases of hypotension, worsening heart failure, and/or arrhythmia have been reported in patients with impaired cardiac function, in which a causal relationship to cinacalcet tablets could not be completely excluded and which may be mediated by reductions in serum calcium levels [see Adverse Reactions (6.2)].

8.2 Lactation

Risk Summary

There are no data regarding the presence of cinacalcet in human milk or effects on the breastfed infant or on milk production. Studies in rats showed that cinacalcet was excreted in the milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for cinacalcet tablets and any potential adverse effects on the breastfed infant from cinacalcet tablets or from the underlying maternal condition.

17 Patient Counseling Information

  • Hypocalcemia: Advise patients to report symptoms of hypocalcemia, including paresthesias, myalgias, muscle spasms, and seizures, to their healthcare provider [see Warnings and Precautions (5.1)]
  • Upper Gastrointestinal Bleeding: Advise patients to report any symptoms of upper gastrointestinal bleeding to their health care provider [see Warnings and Precautions (5.2)]
  • Heart Failure: Advise patients with heart failure that use of cinacalcet tablets may worsen their heart failure and additional monitoring may be required [see Warnings and Precautions (5.3)].
  • Advise patients to report nausea and vomiting to their health care provider [see Adverse Reactions (6.1)].
  • Advise patients to take cinacalcet tablets with food or shortly after a meal and to take the tablets whole and not divide them [see Dosage and Administration (2.1)].
  • Inform patients of the importance of regular blood tests, in order to monitor the safety and efficacy of cinacalcet tablets therapy.
  •  10000023/06
  •  Revised May 2024
  •  Manufactured by:
    Piramal Pharma Limited,
    Plot No. 67-70 Sector 2,
  •  Pithampur-454775, Dist. Dhar, Madhya Pradesh, INDIA
  •  Mfg Lic. No.: 25/10/92
  •  Distributed by:
  •  Slate Run Pharmaceuticals, LLC.
  •  Columbus, Ohio 43215

* Please review the disclaimer below.